RLAY — Relay Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.09bn
- $493.77m
- $10.01m
- 66
- 13
- 91
- 59
Annual cashflow statement for Relay Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52.4 | -364 | -291 | -342 | -338 |
| Depreciation | |||||
| Non-Cash Items | 31.5 | 188 | 45.6 | 68.8 | 68.5 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -85.2 | 97.3 | 11.2 | -32.5 | 14.6 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -102 | -74.4 | -229 | -300 | -249 |
| Capital Expenditures | -1.93 | -3.47 | -9.06 | -4.13 | -2.02 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 83.6 | -476 | -180 | 262 | -39.1 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 81.7 | -480 | -189 | 258 | -41.1 |
| Financing Cash Flow Items | -2.51 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 427 | 388 | 290 | 34.8 | 270 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 406 | -166 | -128 | -7.93 | -20 |